Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide.
Sparano JA, Moulder S, Kazi A, Vahdat L, Li T, Pellegrino C, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Sebti SM. Sparano JA, et al. Among authors: wright jj. J Clin Oncol. 2006 Jul 1;24(19):3013-8. doi: 10.1200/JCO.2005.04.9114. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769985 Clinical Trial.
A phase II study of the farnesyl transferase inhibitor, tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children's Oncology Group study.
Fouladi M, Nicholson HS, Zhou T, Laningham F, Helton KJ, Holmes E, Cohen K, Speights RA, Wright J, Pollack IF; Children's Oncology Group. Fouladi M, et al. Cancer. 2007 Dec 1;110(11):2535-41. doi: 10.1002/cncr.23078. Cancer. 2007. PMID: 17932894 Free article. Clinical Trial.
Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.
Sparano JA, Moulder S, Kazi A, Coppola D, Negassa A, Vahdat L, Li T, Pellegrino C, Fineberg S, Munster P, Malafa M, Lee D, Hoschander S, Hopkins U, Hershman D, Wright JJ, Kleer C, Merajver S, Sebti SM. Sparano JA, et al. Among authors: wright jj. Clin Cancer Res. 2009 Apr 15;15(8):2942-8. doi: 10.1158/1078-0432.CCR-08-2658. Epub 2009 Apr 7. Clin Cancer Res. 2009. PMID: 19351752 Free PMC article. Clinical Trial.
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma.
Badros A, Burger AM, Philip S, Niesvizky R, Kolla SS, Goloubeva O, Harris C, Zwiebel J, Wright JJ, Espinoza-Delgado I, Baer MR, Holleran JL, Egorin MJ, Grant S. Badros A, et al. Among authors: wright jj. Clin Cancer Res. 2009 Aug 15;15(16):5250-7. doi: 10.1158/1078-0432.CCR-08-2850. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671864 Free PMC article. Clinical Trial.
Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer.
Haigentz M Jr, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, Gaba AG, Smith RV, Shapiro GI, Chirieac LR, Mariadason JM, Belbin TJ, Greally JM, Wright JJ, Haddad RI. Haigentz M Jr, et al. Among authors: wright jj. Oral Oncol. 2012 Dec;48(12):1281-8. doi: 10.1016/j.oraloncology.2012.05.024. Epub 2012 Jun 28. Oral Oncol. 2012. PMID: 22748449 Free PMC article. Clinical Trial.
Phase I trial of a new schedule of romidepsin in patients with advanced cancers.
Amiri-Kordestani L, Luchenko V, Peer CJ, Ghafourian K, Reynolds J, Draper D, Frye R, Woo S, Venzon D, Wright J, Skarulis M, Figg WD, Fojo T, Bates SE, Piekarz RL. Amiri-Kordestani L, et al. Clin Cancer Res. 2013 Aug 15;19(16):4499-507. doi: 10.1158/1078-0432.CCR-13-0095. Epub 2013 Jun 11. Clin Cancer Res. 2013. PMID: 23757352 Free PMC article. Clinical Trial.
368 results